Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Buy” by Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $14.67.

ZURA has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Zura Bio in a research report on Thursday, April 3rd. Chardan Capital decreased their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, March 26th. Oppenheimer reissued an “outperform” rating and issued a $19.00 price target (down from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. Finally, Guggenheim reissued a “buy” rating and issued a $15.00 price target on shares of Zura Bio in a report on Wednesday, March 26th.

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Advisers LP acquired a new stake in shares of Zura Bio in the fourth quarter worth approximately $32,000. Shay Capital LLC acquired a new stake in shares of Zura Bio in the fourth quarter worth approximately $233,000. ProShare Advisors LLC acquired a new stake in shares of Zura Bio in the fourth quarter worth approximately $35,000. Millennium Management LLC boosted its position in shares of Zura Bio by 1,499.0% in the fourth quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock worth $1,753,000 after acquiring an additional 657,420 shares during the last quarter. Finally, Forefront Analytics LLC boosted its position in shares of Zura Bio by 74.4% in the fourth quarter. Forefront Analytics LLC now owns 53,734 shares of the company’s stock worth $134,000 after acquiring an additional 22,924 shares during the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Price Performance

Zura Bio stock opened at $1.41 on Tuesday. The stock’s 50 day moving average price is $1.27 and its 200 day moving average price is $2.28. The company has a market cap of $96.41 million, a PE ratio of -2.66 and a beta of 0.08. Zura Bio has a 1-year low of $0.97 and a 1-year high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The firm had revenue of $0.00 million for the quarter. On average, equities research analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.